Centhaquine Restores Renal Blood Flow and Protects Tissue Damage After Hemorrhagic Shock and Renal Ischemia
- PMID: 34012389
- PMCID: PMC8126696
- DOI: 10.3389/fphar.2021.616253
Centhaquine Restores Renal Blood Flow and Protects Tissue Damage After Hemorrhagic Shock and Renal Ischemia
Abstract
Background: Centhaquine (CQ) (Lyfaquin®) is in late stage clinical development as a safe and effective first-in-class resuscitative agent for hemorrhagic shock patients (NCT02408731, NCT04056065, and NCT04045327). Acute kidney injury (AKI) is known to be associated with hemorrhagic shock. Hence, effect of CQ on protection of kidneys from damage due to hemorrhagic shock was investigated. Methods: To assess effect of CQ on AKI in shock, we created a rat model with hemorrhagic shock and AKI. Renal arteries were clamped and de-clamped to induce AKI like ischemia/reperfusion model and hemorrhage was carried out by withdrawing blood for 30 min. Rats were resuscitated with CQ (0.02 mg/kg) for 10 min. MAP, heart rate (HR), and renal blood flow (RBF) were monitored for 120 min. Results: CQ produced a significant improvement in RBF compared to vehicle (p< 0.003) even though MAP and HR was similar in CQ and vehicle groups. Blood lactate level was lower (p = 0.0064) in CQ than vehicle at 120 min post-resuscitation. Histopathological analysis of tissues indicated greater renal damage in vehicle than CQ. Western blots showed higher HIF-1α (p = 0.0152) and lower NGAL (p = 0.01626) levels in CQ vs vehicle. Immunofluorescence in the kidney cortex and medulla showed significantly higher (p< 0.045) expression of HIF-1α and lower expression of Bax (p< 0.044) in CQ. Expression of PHD 3 (p< 0.0001) was higher, while the expression of Cytochrome C (p = 0.01429) was lower in the cortex of CQ than vehicle. Conclusion: Results show CQ (Lyfaquin®) increased renal blood flow, augmented hypoxia response, decreased tissue damage and apoptosis following hemorrhagic shock induced AKI, and may be explored to prevent/treat AKI. Translational Statement: Centhaquine (CQ) is safe for human use and currently in late stage clinical development as a first-in-class resuscitative agent to treat hemorrhagic shock. In the current study, we have explored a novel role of CQ in protection from hemorrhagic shock induced AKI, indicating its potential to treat/prevent AKI.
Keywords: acute kidney injury; centhaquine; hemorrhage; hypoxia inducible factors; resuscitation; shock.
Copyright © 2021 Ranjan, Zhang, Briyal and Gulati.
Conflict of interest statement
AG is an employee of Pharmazz, Inc., and has issued and pending patents related to this study. Midwestern University is the patent assignee with AG as an inventor of this technology, while Pharmazz Inc. holds its exclusive worldwide license and is engaged in the clinical development and commercialization of centhaquine (CQ) for human use. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Controls of Central and Peripheral Blood Pressure and Hemorrhagic/Hypovolemic Shock.J Clin Med. 2023 Jan 31;12(3):1108. doi: 10.3390/jcm12031108. J Clin Med. 2023. PMID: 36769755 Free PMC article. Review.
-
Role of adrenergic receptors in shock.Front Physiol. 2023 Jan 16;14:1094591. doi: 10.3389/fphys.2023.1094591. eCollection 2023. Front Physiol. 2023. PMID: 36726848 Free PMC article. Review.
-
A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients.Drugs. 2021 Jun;81(9):1079-1100. doi: 10.1007/s40265-021-01547-5. Epub 2021 Jun 1. Drugs. 2021. PMID: 34061314 Free PMC article. Clinical Trial.
-
A multicentric, randomized, controlled phase III study of centhaquine (Lyfaquin ® ) as a resuscitative agent in hypovolemic shock patients.medRxiv [Preprint]. 2021 May 9:2020.07.30.20068114. doi: 10.1101/2020.07.30.20068114. medRxiv. 2021. PMID: 33173916 Free PMC article. Updated. Preprint.
-
Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial.Adv Ther. 2021 Jun;38(6):3223-3265. doi: 10.1007/s12325-021-01760-4. Epub 2021 May 10. Adv Ther. 2021. PMID: 33970455 Free PMC article. Clinical Trial.
Cited by
-
Controls of Central and Peripheral Blood Pressure and Hemorrhagic/Hypovolemic Shock.J Clin Med. 2023 Jan 31;12(3):1108. doi: 10.3390/jcm12031108. J Clin Med. 2023. PMID: 36769755 Free PMC article. Review.
-
Role of adrenergic receptors in shock.Front Physiol. 2023 Jan 16;14:1094591. doi: 10.3389/fphys.2023.1094591. eCollection 2023. Front Physiol. 2023. PMID: 36726848 Free PMC article. Review.
-
Pathophysiology of Hemorrhage as It Relates to the Warfighter.Physiology (Bethesda). 2022 May 1;37(3):141-153. doi: 10.1152/physiol.00028.2021. Epub 2022 Jan 10. Physiology (Bethesda). 2022. PMID: 35001653 Free PMC article. Review.
References
-
- Ak Ranjan M. J., Hardikar A. A. (2015). Characterizing cellular identity at one cell resolution. New York, NY: Humana Press.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
